GlassScriptPhysician profile
Vikash K Sinha
NPI 1740628726
$1,313.62
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $61.32 · 2022: $415 · 2023: $189 · 2024: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371 · Education: $33.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.43 |
| Education | $33.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $329.18 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $291.32 | 2019-2024 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $182.26 | 2019-2024 | |
| Vifor Pharma, INC. | $171.67 | 2020-2023 | Veltassa, Korsuva |
| Genentech USA, INC. | $120.17 | 2019 | |
| Lilly USA, LLC | $64.74 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $51.31 | 2022-2023 | Jynarque |
| Aurinia Pharma U.S., INC. | $25.92 | 2023 | Lupkynis |
| Fresenius USA Marketing, INC. | $23.30 | 2022 | |
| Opko Pharmaceuticals, LLC | $18.99 | 2022 | |
| Glaxosmithkline, LLC. | $18.32 | 2024 | Jesduvroq |
| Ardelyx, INC. | $16.44 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikash Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.